CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹-31 Cr | ₹82 Cr | ₹184 Cr | ₹622 Cr | ₹1,660 Cr |
What is the latest Total Non-Current Liabilities ratio of CIPLA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹-31 Cr |
| Mar2024 | ₹82 Cr |
| Mar2023 | ₹184 Cr |
| Mar2022 | ₹622 Cr |
| Mar2021 | ₹1,660 Cr |
How is Total Non-Current Liabilities of CIPLA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹-31 Cr | Negative | |
| Mar2024 | ₹82 Cr | -55.36 | |
| Mar2023 | ₹184 Cr | -70.48 | |
| Mar2022 | ₹622 Cr | -62.55 | |
| Mar2021 | ₹1,660 Cr | - | |
Compare Total Non-Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹108,863.2 Cr | 1.6% | 1.8% | -7.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹417,028.0 Cr | 0.3% | 9% | 8.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,237.0 Cr | 1.9% | 5.9% | 12.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,801.0 Cr | 0.6% | 9.5% | 45% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,435.0 Cr | -1.5% | 5.7% | 14.5% | Stock Analytics | |
| MANKIND PHARMA | ₹92,784.1 Cr | 9.9% | 5.8% | -2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 1.6% |
1.8% |
-7.9% |
| SENSEX | -1.8% |
-1.6% |
7.3% |
You may also like the below Video Courses